A new cardioprotective drug for acute treatment of myocardial infarction

Ischemic Heart Disease kills more than 1.7M people/year in the EU, the vast majority via a heart attack (Myocardial Infarction - MI). Heart failure (HF) is the major cause of death after MI with a prevalence of >26M individuals globally. While current treatment involving restoration of blood flow to the heart saves the MI patients life it also causes additional damage to the heart through an inflammatory reaction (reperfusion injury). ResoThers leading drug candidate, RTP-026, is an immunomodulating therapeutic aimed at resolving inflammation triggered during MI, thereby reducing damage to the heart and significantly decreasing risk of HF and death. Pre-clinical data suggests RTP-026 could reduce post-MI HF by >20%. A Phase I study has been conducted to determine safety and tolerability of RTP-026 in Healthy Volunteers. With the EIC we aim to validate RTP-026 clinical effectiveness by means of a Phase IIa patient proof of principle study and Phase IIb proof of concept study.